# Cencora, Inc. (COR) — Stock CV

Cencora, Inc. is a $61.8B healthcare company. Revenue grew 5.1% over the last year, it keeps 1¢ of every dollar of sales as profit, and its net debt equals ~0.8 years of free cash flow. It trades at 23.5× earnings — in the cheapest third of its own history.

> Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers.

## Identity

- **Ticker**: COR
- **Sector**: Healthcare
- **Industry**: Wholesale-Drugs, Proprietaries & Druggists' Sundries
- **Headquarters**: CONSHOHOCKEN, PA
- **Employees**: 51 000
- **Website**: https://www.cencora.com
- **Market cap**: $61.8B
- **Last price**: $323.85
- **Financial profile**: Solid

## Vitals (TTM)

- **Revenue**: $333B
- **Net income**: $2.62B
- **Free cash flow**: $4.06B
- **Net debt**: $3.30B
- **P/E**: 23.5
- **Revenue growth (YoY)**: 5.1%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 82 |
| Growth | 57 |
| Profitability | 61 |
| Health | 69 |
| Quality | 92 |
| Moat | 62 |

## Qualifications (beginner checklist) — 10 of 11 passed

- [x] Revenue growing — +5.1% YoY
- [x] Profitable — $2.62B TTM
- [ ] Profit growing — -0.4% YoY
- [x] Generates cash — $4.06B TTM
- [x] Debt under control — ~0.8y of cash flow to repay
- [x] Established company — $61.8B market cap
- [x] Not printing shares — -6.3% shares over ~5y
- [x] Proven track record — 5/5 profitable years
- [x] Financially stable — Altman Z 3.7 — safe
- [x] Pays a dividend — yield 0.76%
- [x] Valuation not extreme — P/E 23.5

## Experience (career milestones)

- **Q2 2026** — 3 open-market insider purchases: ~9K shares bought by insiders
- **FY2023** — Best year on record: $1.75B net income
- **2023** — It was renamed to Cencora in 2023
- **FY2021** — Profitable every year on record: 5 consecutive profitable years in our data
- **FY2021** — Revenue already above $100B: $214B in first reported year
- **FY2021** — Positive free cash flow every year since: 5-year streak
- **Jan 3, 2018** — In October, they agreed to buy PharMEDium, a compounding drug company, for $2.58 billion
- **2011** — The company acquired IntrinsiQ for $35 million and Premier Source for an undisclosed amount
- **2001** — Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a…

## Strengths

- Interest covered 8.6× by operating earnings
- High returns on invested capital (ROIC 32.3%)
- Piotroski F-Score 7/9 — fundamentally strong checklist
- Altman Z-Score 3.66 — low bankruptcy-risk zone

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $214B | $1.54B | $2.23B |
| FY2022 | $239B | $1.70B | $2.21B |
| FY2023 | $262B | $1.75B | $3.45B |
| FY2024 | $294B | $1.51B | $3.00B |
| FY2025 | $321B | $1.55B | $3.21B |

---

Source: https://stockcv.com/COR — derived from company filings; may be delayed or incomplete. Information, not investment advice.